Misc Drugs denials in California external review
In the California DMHC record, independent physician reviewers decided 12 published external-review cases involving Misc Drugsand overturned the plan’s denial in 100%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Misc Drugs denials
| Category | Decisions | Overturned |
|---|---|---|
| Arthritis Oth Joint Dis | 9 | 100% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Durolane injection to the right knee. Evidence from randomized trials and current medical literature has revealed varied results, as viscosupplementation may relieve some knee pain in individuals with osteoarthritis. However, the evidence concerning which individuals may benefit from viscosupplementation is unknown. In an effort to establish a more effective treatment, different studies have tried mixing hyaluronic acid with corticosteroids, platelet-rich plasma, and other agents. However, guidelines from the leading experts indicate that confirmatory evidence is limited and not conclusive. As such, the leading experts do not currently recommend viscosupplementation as routine treatment for osteoarthritis of the knees.
Findings: The physician reviewer found that a patient has requested authorization and coverage for Durolane injections in both knees. Evidence from systematic reviews and randomized controlled trials indicates that although viscosupplementation may relieve knee pain in some patients with osteoarthritis, data have not established which patients will benefit. Guidelines from the American Academy of Orthopedic Surgeons (AAOS) indicate that the data on the safety and efficacy of viscosupplementation remain inconclusive, and it is not recommended as routine treatment. Viscosupplementation is generally reserved for patients with a history of lasting benefit from prior injections or when remaining options are limited.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Misc Drugs, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY